Public–private relationships in biobanking: a still underestimated key component of open innovation
- 784 Downloads
Access to human bioresources is essential to the understanding of human diseases and to the discovery of new biomarkers aimed at improving the diagnosis, prognosis, and the predictive response of patients to treatments. The use of biospecimens is strictly controlled by ethical assessment, which complies with the laws of the country. These laws regulate the partnerships between the biobanks and industrial actors. However, private–public partnerships (PPP) can be limiting for several reasons, which can hamper the discovery of new biological tests and new active molecules targeted to human diseases. The bottlenecks and roadblocks in establishing these partnerships include: poor organization of the biobank in setting up PPP, evaluation of the cost of human samples, the absence of experience on the public side in setting up contracts with industry, and the fact that public and private partners may not share the same objectives. However, it is critical, in particular for academic biobanks, to establish strong PPP to accelerate translational research for the benefits of patients, and to allow the sustainability of the biobank. The purpose of this review is to discuss the main bottlenecks and roadblocks that can hamper the establishment of PPP based on solid and trusting relationships.
KeywordsBiobank Research Public–private partnerships Bottlenecks Contracts Private company Indicators
This work was supported by the National Infrastructure “Biobanques” (Grant ANR, France).
Conflict of interest
The authors declare that they have no conflict of interest.
- 5.OECD (2001) Biological resource centres: underpinning the future of life sciences and biotechnology. OECD, Paris, FranceGoogle Scholar
- 6.OECD (2004) Guidance for the operation of biological research centres (BRCs): certification and quality criteria for BRCs. OECD, Paris, FranceGoogle Scholar
- 7.National Cancer Institute, National Institutes of Health. National Cancer Institute Best Practices for Biospecimen Resources 2007. U.S.Department of Health and Human Services. http://biospecimens.cancer.gov/global/pdfs/NCI_Best_Practices_060507.pdf. Accessed 9 Dec 2013
- 10.Hofman V, Ilie M, Long E, Washetine K, Chabannon C, Figarella-Branger D, Clément B, Mabile L, Cambon-Thomsen A, Boucher P, Dagher G, Hewitt R, Parodi B, Hofman P (2013) Measuring the contribution of tumor biobanks to research in oncology: surrogate indicators and bibliographic output. Biopreserv Biobanking 11(4):235–244CrossRefGoogle Scholar
- 11.Cambon-Thomsen A, Thorisson GA, Mabile L, Andrieu S, Bertier G, Boeckhout M, Cambon-Thomsen A, Carpenter J, Dagher G, Dalgleish R, Deschênes M, di Donato JH, Filocamo M, Goldberg M, Hewitt R, Hofman P, Kauffmann F, Leitsalu L, Lomba I, Mabile L, Melegh B, Metspalu A, Miranda L, Napolitani F, Oestergaard MZ, Parodi B, Pasterk M, Reiche A, Rial-Sebbag E, Rivalle G, Rochaix P, Susbielle G, Tarasova L, Thomsen M, Thorisson GA, Zawati MH, Zins M, BRIF workshop group (2011) The role of a bioresource research impact factor as an incentive to share human bioresources. Nat Genet 43(6):503–504PubMedCrossRefGoogle Scholar
- 19.Mabile L, Dalgleish R, Thorisson GA, Deschênes M, Hewitt R, Carpenter J, Bravo E, Filocamo M, Gourraud PA, Harris JR, Hofman P, Kauffmann F, Muñoz-Fernàndez MA, Pasterk M, Cambon-Thomsen A (2013) Quantifying the use of bioresources for promoting their sharing in scientific research. Gigascience 2(1):7. doi: 10.1186/2047-217X-2-7 PubMedCentralPubMedCrossRefGoogle Scholar
- 21.Chabannon C, Honstettre A, Daufresne LM, Martin PM, Bonnetaud C, Birtwisle-Peyrottes I, Romain S, Achache K, Mery O, Bordonne O, Ducord C, Jacotot L, Vaglio P, d’Arnoux C, Figarella-Branger D, Hofman P, Borg JP, Atger V (2010) Publication of biological samples collections catalogues by tumor banks. Bull Cancer 97(2):181–189PubMedGoogle Scholar
- 23.Rahm AK, Wrenn M, Carroll NM, Feigelson HS (2013) Biobanking for research: a survey of patient population attitudes and understanding. J Community Genet(Apr 20)Google Scholar
- 24.Hofman V, Bonnetaud C, Gaziello MC, Ilie M, Lassalle S, Butori C, Lerda N, Selva E, Gavric-Tanga V, Castillo L, Guevara N, Santini J, Pop D, Vénissac N, Mouroux J, Chabannon C, Hofman P (2010) The Nice CHU biobank experience to collect patients’ informed consent for research context (2004–2009). Ann Pathol 30(5):337–343PubMedCrossRefGoogle Scholar